Takimoto M, Oki J, Yoshioka H, Takase A, Nagamatsu I
Jpn J Antibiot. 1982 Mar;35(3):766-9.
9, 3"-Diacetylmidecamycin (MOM), a new macrolide antibiotic, was administered to 28 patients: 6 with pharyngitis caused by Group A beta-Streptococcus, 2 with lacunar tonsillitis, 8 with upper respiratory tract infection, 6 with acute bronchitis, 3 with Mycoplasma pneumonia, 1 with primary atypical pneumonia, 1 with pneumonia caused by H. influenzae and 1 with whooping cough. MOM in the form of fine granules was administered at a daily dose of about 20-30 mg/kg divided into 3 doses. Isolated group A beta-Streptococcus strains were eradicated in only 1 out of 6 strain S. One strain of H. influenzae was eradicated. The clinical results could be obtained with 21 cases and the response was excellent in 1 case, good in 7, fair in 3 and poor in 10. Although diarrhea was found in 3 cases during the administration of MOM, it was not clear whether these phenomena were caused by MOM, because of the prevalence of diarrhea among the children treated by us at that time.
9,3”-二乙酰麦迪霉素（MOM），一种新型大环内酯类抗生素，应用于28例患者：6例A组β溶血性链球菌引起的咽炎，2例陷窝性扁桃体炎，8例上呼吸道感染，6例急性支气管炎，3例支原体肺炎，1例原发性非典型肺炎，1例流感嗜血杆菌引起的肺炎，1例百日咳。MOM以细颗粒剂形式给药，日剂量约20 - 30mg/kg，分3次服用。6株A组β溶血性链球菌菌株中仅1株被清除。1株流感嗜血杆菌被清除。21例获得临床结果，其中1例疗效极佳，7例良好，3例尚可，10例较差。虽然在服用MOM期间有3例出现腹泻，但由于当时我们治疗的儿童中腹泻普遍存在，尚不清楚这些现象是否由MOM引起。
